Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05288023
Other study ID # 19-28387C
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date December 1, 2022
Est. completion date March 2027

Study information

Verified date August 2023
Source University of California, San Francisco
Contact Elodie Lebas
Phone 5104232245
Email elodie.lebas@ucsf.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The MORDOR trial found that biannual distribution of azithromycin to children 1-59 months old reduced child mortality. The World Health Organization (WHO) released conditional guidelines for this intervention, which include targeting azithromycin distributions to children 1-11 months of age in high mortality settings. The proposed trial aims to demonstrate and evaluate large-scale implementation of azithromycin to children aged 1-11 months old in the context of a programmatic setting while monitoring mortality and resistance antimicrobial resistance.


Description:

In the Programmatic Trial, community health centers (also known as "CSIs" or "Centres de Santé Intégrés") will be randomized to one of two arms: 1) programmatic azithro 1-11: biannual oral azithromycin administration to children aged 1-11 months distributed by community health workers or 2) no intervention: no distribution of azithromycin. A total of 2,490 communities within selected CSIs will be included . All communities in both arms receive routine health services offered by community health workers working for the Niger Ministry of Health's community health program. Mortality will be monitored through birth histories. Mortality and morbidity will also be monitored using routinely collected community and clinic visit data. Antimicrobial resistance will be monitored in a subset of eligible CSIs.


Recruitment information / eligibility

Status Recruiting
Enrollment 250000
Est. completion date March 2027
Est. primary completion date March 2027
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 1 Month and older
Eligibility Intervention At the community-level, eligibility includes: Inclusion Criteria: - Location in Dosso, Tahoua, Maradi, Zinder, or Tillabéri regions - Distinguishable from neighboring communities - Verbal consent of community leader(s) Exclusion criteria: - Inaccessible or unsafe for study team - "Quartier" designation on national census At the individual-level, eligibility includes: Inclusion criteria: - Age 1-11 months - Primary residence in a study community - Verbal consent of caregiver/guardian for study participation Exclusion criteria: - Known allergy to macrolides Population-based sample collections At the community-level, eligibility includes: Inclusion criteria: - Location in study region - Distinguishable from neighboring communities - Verbal consent of community leader(s) Exclusion criteria: - Inaccessible or unsafe for study team - Included in MORDOR trials - Not randomly selected At the individual-level, eligibility includes: Inclusion criteria: - Age 1-59 months or 7-12 years or caregiver/guardian of a child eligible for treatment - Primary residence in a study community selected for sample collections - Verbal consent of caregiver/guardian for study participation Exclusion criteria: - Not on list of randomly selected participants from the census

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Azithromycin for Oral Suspension
Azithromycin will be administered as a single dose in oral suspension form for children (up to the maximum adult dose of 1g). Dosage will be calculated by age for children aged 1-5 months. For children 6-59 months of age, height-based dosing will be used via height-stick approximation as currently performed by Niger's trachoma program.

Locations

Country Name City State
United States Proctor foundation San Francisco California

Sponsors (3)

Lead Sponsor Collaborator
University of California, San Francisco Bill and Melinda Gates Foundation, Ministry of Health, Niger

Country where clinical trial is conducted

United States, 

References & Publications (2)

Keenan JD, Bailey RL, West SK, Arzika AM, Hart J, Weaver J, Kalua K, Mrango Z, Ray KJ, Cook C, Lebas E, O'Brien KS, Emerson PM, Porco TC, Lietman TM; MORDOR Study Group. Azithromycin to Reduce Childhood Mortality in Sub-Saharan Africa. N Engl J Med. 2018 Apr 26;378(17):1583-1592. doi: 10.1056/NEJMoa1715474. — View Citation

WHO Guideline on Mass Drug Administration of Azithromycin to Children under Five Years of Age to Promote Child Survival [Internet]. Geneva: World Health Organization; 2020. No abstract available. Available from http://www.ncbi.nlm.nih.gov/books/NBK561641/ — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Prevalence of genetic determinants of macrolide resistance from population-based samples Prevalence of genetic determinants of macrolide resistance including those determinants known to be found in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus in nasopharyngeal swabs in children aged 1-59 months from population-based samples after 1 year of distribution 2 years
Primary Load of genetic determinants of macrolide resistance from population-based samples Load of genetic determinants of resistance to macrolides including those determinants known to be found in Campylobacter spp, Salmonella spp, Shigella spp, and Escherichia coli from rectal swabs in children 1-59 months old from population-based samples, defined as read number per million base pairs, using DNA-seq (metagenomic deep sequencing). 2 years
Secondary Prevalence of genetic determinants of macrolide resistance from clinic-based samples Prevalence of resistance to macrolides including those determinants known to be found in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus from nasopharyngeal swabs in children 1-59 months old. 2 years
Secondary Load of genetic determinants of macrolide resistance from clinic-based samples Load of genetic determinants of resistance to macrolides including those determinants known to be found in Campylobacter spp, Salmonella spp, Shigella spp, and Escherichia coli from rectal swabs in children 1-59 months old, defined as read number per million base pairs, using DNA-seq (metagenomic deep sequencing). 2 years
Secondary Number of all-cause clinic visits Number of all-cause clinic visits per month for children aged 1-59 months over 1 year 2 years
See also
  Status Clinical Trial Phase
Completed NCT03079726 - Use of Device Data to Predict Frailty in Individuals
Not yet recruiting NCT05447611 - Role of Empathy in Curative Treatment Outcomes of Non-metastatic Colorectal Cancer.
Completed NCT05268419 - Efficacy and Safety of Ethanol Inhalation on COVID-19 Treatment (a Clinical Trial Study) Phase 3
Completed NCT05042804 - Perioperative Outcome Risk Assessment With Computer Learning Enhancement N/A
Recruiting NCT03628313 - Valvular Aortic Stenosis Prognosis Study
Completed NCT05527678 - 5 Years Quality of Life and Early Mobilization in ICU
Recruiting NCT05088109 - Shock Indices Use for Early Mortality From Septic Shock
Recruiting NCT05073991 - Incidence of Mortality and Complications After Lung Surgery, Open Thoracic Aortic Repair, TEVAR, EVAR.
Completed NCT05844410 - Evaluation of Corticosteroids Use and Clinical Outcomes in Hospitalized COVID-19 Patients: A Retrospective Study
Recruiting NCT05585593 - Registry for Hypoparathyroidism Wuerzburg
Recruiting NCT03834246 - Smoke Inhalation Injury in Patients Admitted to Intensive Care
Completed NCT03919032 - Bacterial Infections in Patients With Cirrhosis in Argentina: Clinical and Microbiological Characteristics
Completed NCT05116670 - Comparison of Care Practices, Mortality and Morbidity of Very Preterm Infants Between Two Tertiary Centers in Northwest and South of China
Withdrawn NCT04531839 - Improving Outcome of Very Preterm Infants Using Collaborative Quality Improvement N/A
Recruiting NCT04685278 - Anticardiolipin Autoantibodies and Mortality in Septic Patients
Not yet recruiting NCT03665987 - The Effect of Preoperative Assessment Clinic on Prognosis and Economic Results of Patients With Coexisting Disease.
Completed NCT04049565 - CRP Versus PCT as Bio-markers for Sepsis and in Guiding Antibiotics in Critically Ill Patients
Completed NCT04971278 - Evaluating the Impact of a Supportive Care Program
Recruiting NCT06087315 - Evaluation of a Multi-country Medical Oxygen Program
Completed NCT03344627 - Clinical Outcome Study of High-dose Meropenem in Sepsis and Septic Shock Patients N/A